Epix touts data on pulmonary hypertension drug

Shares of Epix Pharmaceuticals were buoyed this morning by positive data from a mid-stage study of a drug designed to reduce high blood pressure in the pulmonary artery. The trial of PRX-08066 involved 71 patients with pulmonary hypertension associated with COPD. Lexington, MA-based Epix also reported that its losses ballooned in the second quarter due to swelling R&D costs.

- see the release for more

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.